Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Julia Sidenius Johansen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-4217-6560; OpenAlex author ID A5063670944. Sources: OpenAlex.

Their work

Papers
53 (first author 4, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
137
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: 4 papers · 2021: 8 papers · 2022: 6 papers · 2023: 12 papers · 2024: 2 papers · 2025: 8 papers · 2026: 1 paper

Papers 50 of 53

  1. Impact of Liver Metastases on Outcomes With Chemotherapy or Immune Checkpoint Inhibitors in Pancreatic Cancer. Co-author DOI 10.1002/iid3.70545↗
  2. A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE). Co-author DOI 10.1016/j.iotech.2025.101054↗
  3. BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target. Co-author DOI 10.1038/s41598-025-24463-0↗
  4. Genome-wide analyses of cell-free DNA for therapeutic monitoring of patients with pancreatic cancer. Co-author DOI 10.1126/sciadv.ads5002↗
  5. The Prognostic Impact of Early ctDNA Kinetics in Metastatic Pancreatic Cancer Using the ctDNA-RECIST. Co-author DOI 10.1158/1078-0432.ccr-25-0758↗
  6. Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ducta… Co-author DOI 10.1186/s12885-025-14283-w↗
  7. Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Surviva… First author DOI 10.1200/jco-25-01631↗
  8. Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cac… First author DOI 10.1200/jco.23.01965↗
  9. Promoter hypermethylation of SFRP1 is an allele fraction-dependent prognostic biomarker in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2025.1568386↗
  10. Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/s41591-023-02694-w↗
  11. Human P2X7 receptor variants Gly150Arg and Arg276His polymorphisms have differential effects on risk association and cellular functions in pancreatic cancer. Co-author DOI 10.1186/s12935-024-03339-9↗
  12. Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer. Last author DOI 10.1002/cam4.5240↗
  13. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  14. Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). Co-author DOI 10.1016/j.ejca.2022.11.035↗
  15. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with stage III or IV pancreatic ductal adenocar… Co-author DOI 10.1016/j.pan.2023.05.003↗
  16. Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101013↗
  17. Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy. Co-author DOI 10.1136/jitc-2022-006432↗
  18. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.1186/s12885-023-11035-6↗
  19. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.21203/rs.3.rs-2955930/v1↗
  20. High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fmolb.2023.1158058↗
  21. Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2023.1211292↗
  22. Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers15030897↗
  23. Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records. Co-author DOI 10.7554/elife.84919↗
  24. Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (Che… First author DOI 10.1200/jco.21.02511↗
  25. Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibro… Co-author DOI 10.3390/biom12091315↗
  26. Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14030819↗
  27. Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy. Last author DOI 10.3390/cancers14133250↗
  28. Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer. Co-author DOI 10.3390/cells11233763↗
  29. A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic C… First author DOI 10.3390/pharmaceutics14030509↗
  30. Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenoc… Co-author DOI 10.1002/ijc.33551↗
  31. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer. Last author DOI 10.1016/j.ejca.2020.10.038↗
  32. Response to the letter entitled: Re: Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival i… Last author DOI 10.1016/j.ejca.2021.09.009↗
  33. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma - An external validation study. Co-author DOI 10.1016/j.pan.2021.05.003↗
  34. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  35. Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification. Last author DOI 10.1158/1078-0432.ccr-20-4215↗
  36. Regional and age differences in specialised palliative care for patients with pancreatic cancer. Co-author DOI 10.1186/s12904-021-00870-8↗
  37. Inflammatory Biomarker Score Identifies Patients with Six-Fold Increased Risk of One-Year Mortality after Pancreatic Cancer. Last author DOI 10.3390/cancers13184599↗
  38. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Last author DOI 10.1002/ijc.32751↗
  39. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, an… Last author DOI 10.1097/mpa.0000000000001466↗
  40. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer. Last author DOI 10.1111/ecc.13219↗
  41. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Last author DOI 10.1158/1055-9965.epi-19-0672↗
  42. Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.1200/jco.2017.77.6658↗
  43. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.17.00121↗
  44. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Co-author DOI 10.1038/bjc.2017.140↗
  45. Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers. Last author DOI 10.1186/s40364-017-0087-6↗
  46. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenoca… Last author DOI 10.18632/oncotarget.22080↗
  47. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.30291↗
  48. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Co-author DOI 10.1038/nm.4082↗
  49. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Co-author DOI 10.1038/ncomms8686↗
  50. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. Last author DOI 10.1001/jama.2013.284664↗

Closest collaborators

The 25 strongest of 137 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Inna Markovna Chen · 33 shared papers, 2017–2025 · strength 5.13
  2. Carsten Palnæs Hansen · 20 shared papers, 2017–2025 · strength 2.84
  3. Astrid Zedlitz Johansen · 16 shared papers, 2020–2025 · strength 2.26
  4. Dorte Lisbet Nielsen · 10 shared papers, 2021–2025 · strength 1.72
  5. Susann Theile · 8 shared papers, 2022–2026 · strength 1.63
  6. Louise S. Rasmussen · 9 shared papers, 2020–2025 · strength 1.29
  7. M.A. Karsdal · 8 shared papers, 2020–2025 · strength 1.25
  8. Nicholas Willumsen · 8 shared papers, 2020–2025 · strength 1.25
  9. Per Pfeiffer · 10 shared papers, 2013–2025 · strength 1.09
  10. Lars Nannestad Jørgensen · 6 shared papers, 2021–2025 · strength 0.98
  11. Hadi M. H. Diab · 6 shared papers, 2021–2025 · strength 0.98
  12. Neel Ingemann Nissen · 6 shared papers, 2021–2025 · strength 0.92
  13. Rasmus S. Pedersen · 4 shared papers, 2022–2025 · strength 0.72
  14. Sidsel C. Lindgaard · 4 shared papers, 2021–2025 · strength 0.68
  15. Benjamin Emil Stubbe · 4 shared papers, 2021–2025 · strength 0.67
  16. Stine Dam Henriksen · 4 shared papers, 2021–2025 · strength 0.67
  17. Ole Thorlacius‐Ussing · 4 shared papers, 2021–2025 · strength 0.67
  18. Lars Henrik Jensen · 3 shared papers, 2023–2025 · strength 0.60
  19. Morten Bækbo Ladekarl · 3 shared papers, 2023–2025 · strength 0.55
  20. Mads Hald Andersen · 2 shared papers, 2023–2026 · strength 0.50
  21. Eric Andrew Collisson · 5 shared papers, 2016–2024 · strength 0.49
  22. Jon Kroll Bjerregaard · 6 shared papers, 2013–2021 · strength 0.47
  23. Katherine R. Pelz · 2 shared papers, 2025 · strength 0.41
  24. Denis C. Guttridge D · 2 shared papers, 2025 · strength 0.41
  25. Teresa A Zimmers · 2 shared papers, 2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.